In order for our immune cells to eliminate tumors and cancerous tissue, the immune cells must first be activated and recognize tumor associated and tumor specific antigens (TAA and TSA) in order to mount a pro-inflammatory response. Thus, the challenge is two-fold: developing targeted therapies that have improved recognition of a specific cancer, and enhancement of T-cell activation. Historically, analysis of antigen recognition has focused on screening of TAA and TSA; however, newer therapies are investigating the use of adoptive cells (including CAR T-cells) to target specific cancers. After T-cells have recognized an antigen and activation has been initiated; activation and stimulation need to be maintained. Cancerous cells have several mechanisms to hide from immune cells, including upregulation of certain cell surface markers (immune checkpoints) that suppress immune function.
Xeno Diagnostics offers a wide range of assays to test immune cell activation and enhancement in response to antigenic and allogeneic stimulation:
Xeno Diagnostics is a CLIA certified high complexity lab and adheres to GLP and GCLP standards. We have had years of experience helping clients navigate the regulatory landscape and produce high-quality assays, documentation, and reporting to fit the regulatory requirements for each stage of product development.